In this thesis, we used genetically engineered mouse models to identify genes and pathways that are involved in ILC formation and in the development of resistance to FGFR-targeted therapy.

Promotor: E. Bouwman, Co-promotor: S. Bonnet

What are the biological effects of Chinese herbal medicine in regulation of cancer cell metastasis?

The potential of liposomal cancer vaccines

G protein-coupled receptors (GPCRs), one of the largest families of membrane proteins, are responsive to a diverse set of physiological endogenous ligands including hormones and neurotransmitters.

PhD defence

PhD defence

PhD defence

From the largest numbers to the smallest molecules and from the oldest galaxies up to the latest algorithms, explore our standout discoveries and most inspiring collaborations from the past year!

Traditional drug discovery approaches have been hampered by (in vitro) cell-culture models that poorly represent the situation in the human body.

Modified viruses can both kill cancer cells and activate the immune system. This is what an LUMC team discovered while researching a new prostate cancer therapy.

As part of the HTSM2017 funding program, the LACDR division for Systems Biomedicine and Pharmacology received 1.08 million euros for a research project to develop novel engineering approaches to fight cancer.

Prostate cancer (PCa) is one of the most prevalent cancer in males.

A therapeutic vaccine against HPV-16 (type 16 human papillomavirus) improves the survival rate in cervical cancer patients. A new study by ISA Pharmaceuticals B.V. (a Leiden-based biotechnology company) and the Leiden University Medical Center (LUMC) shows that this vaccine produces a more robust response…

Winning a prestigious award for PhD researchers, even before you have your doctorate: that's what Yascha van den Berg managed to do with his research proposal on alternatively spliced tissue factor, a protein that may be involved in tumour growth. Van den Berg: ‘It all started as a Friday afternoon…

PhD student Esmee Koedoot studied the underlying processes responsible for metastases in a dangerous type of breast cancer. She hopes to find new possibilities to fight the disease. In December 2019 she obtained her doctorate cum laude.

Zebrafish-human communication shows that cancer cells lacking a signaling protein are less able to develop aggressive metastatic properties. This discovery has been made by molecular cell biologist Claudia Tulotta. PhD defence 14 June.

We already know a lot about genetics and the risk of breast cancer. But much still needs to be done in breast cancer genetics to improve the prognosis and make sure women at high risk aren’t missed. This is what Professor by Special Appointment Marjanka Schmidt will say in her inaugural lecture on 4…

Leiden biophysicist Stefano Coppola has received the prestigious AXA Research Fund postdoctoral fellowship. With this grant he can work for two years on a project to research the role of mechanical factors in the development of pancreatic cancer.

Leiden PhD student Xuequan Zhou has designed a new promising molecule that efficiently kills cancer cells, but does not harm healthy tissue. The trick: the drug is only active when irradiated with light. Zhou’s new compound does this extra efficiently by cleverly self-organising into nanoparticles.…

Cancer is one of the main causes of death in the Netherlands. Leiden researchers are working to improve the treatment of different types of cancer in order to increase the patient’s quality of life. A better understanding of how cancer develops will make it possible to deliver personalised and precise…

Professor of Cardiothoracic Surgery, in particular pulmonary surgery, Jerry Braun will give his inaugural lecture on Friday 23 September entitled ‘Out of countless millions’. Braun has been a professor and acting head of the LUMC’s Department of Cardiothoracic Surgery since January 2020. Covid meant…

Ewa Snaar-Jagalska, Shuning He and colleagues from IBL, LION and LACDR reported on a new zebrafish study to understand micrometastasis of human cancer cells. They discovered a novel role for neutrophils in assisting metastasis formation, which provides critical insights for anti-cancer therapies.

As of April 1, 2018, Erik Danen has been appointed as Professor of Cancer drug target discovery at the Leiden Academic Centre for Drug Research (LACDR). His discipline is cell biology of cancer, in which he focuses on the mechanisms underlying metastasis and therapy resistance.

PhD defence

PhD defence

PhD defence

PhD defence

Leiden University Medical Center (LUMC) has spent the past five years coordinating an international study of genetic mutations and breast cancer risks. The results will make it easier to determine which genes increase the risk of breast cancer and to what extent. The researchers published their results…

Ariane Briegel wants to use bacteria to detect cancer at an early stage. Together with postdoc Alise Muok, she is developing a method to quickly and cheaply test the urine of patients for the presence of suspicious molecules. They receive a grant of approximately 150,000 euros from the Dutch Cancer…

Sebastian Pomplun manages to reach proteins with drugs even where this was thought impossible. That is why he and his research group have been allowed to join Oncode Institute. With nine others, he had been selected from 72 applicants to contribute to Oncode Institute's mission: to accelerate breakthroughs…

To inhibit proteins that contribute to the growth of aggressive cancer cells, that’s the plan of Professor Bob van de Water and his team. They will receive over 700,000 euros from the KWF Dutch Cancer Society for their research. Researcher Maaike Vreeswijk and pathologist Danielle Cohen are affiliated…

In this project, we aim to obtain a quantitative understanding of the role of the immune system in tumor regression, of the role of tumor cell heterogeneity in cancer growth and of tumor cell migration properties.

With a Vici grant of 1.5 million euros, Professor of Mathematical biology Roeland Merks will look for ways to fix messy and leaky blood vessels in tumours. His research combines mathematical simulations and lab experiments in a unique way.

Providing each cancer patient with the right treatment remains a challenge. Oncode Accelerator aims to change this by innovating the way we develop cancer treatments, thus ensuring the patient is at the heart of the process. Leiden University, the LUMC and other partners will implement this new way…

Leiden researchers have carried out successful tests using a new method of packaging a cancer vaccine in nano-particles. The new vaccine has induced a strong immune reaction in mice. The researchers believe that this method can make an important contribution to the treatment of cancer. Their findings…

Three fundamental research projects at Leiden in physics, chemistry and medical science have received funding from the Dutch Research Council (NWO). They involve research on magnetic fields in the universe, the role of myeloid cells in cancer immunotherapy and the evolution of ancient proteins.

Patients with incurable cancer want their oncologist to be clear but to show empathy too. They find hard and vague communication harmful. These are the results of a study by psychologists from Leiden that has been published in the American journal Cancer.

Chemist Gerjan de Bruin has designed a method of slowing down the degradation process of proteins in cells. This may contribute to new cancer medicines with fewer side-effects. PhD defence on 1 June.

An international group of scientists has discovered that certain cells of our immune system – the so-called T cells – communicate with each other and work together as a team. To fight an infection they stimulate each other’s growth, but at the same time, they inhibit each other when there is a surplus…

In breast cancer, metastasis rather than the primary tumour is the cause of death. A lack of oxygen in the tumour cells promotes this metastasis, accompanied by a reprogramming of the cell's metabolism. PhD candidate Qiuyu Liu investigated these alterations to get more knowledge about the actionable…

PhD defence

Cell biologist Erik Danen has been awarderd a grant of half a million euros to study how tumor cells spread throughout the body en develop drug resistance. This was announced mid-August by the Dutch Cancer Society Fund (KWF).

Researchers of the Leiden University Medical Centre (LUMC) and the Leiden Institute of Chemistry have made an important discovery about the commonly used anti-cancer drug doxorubicin. They have found a way to reduce its side effects without sacrificing the effectiveness of the medication. This is encouraging…

Biological chemist Nathaniel Martin and his team received an NWO grant to examine how blocking a specific enzyme in our body, NNMT, could be helpful in the treatment of some cancers. Trials with mice have been promising, and together with the Netherlands Cancer Institute, Martin wants to take the next…

A cancer pill, preferably without severe side effects, is something we’d all welcome. Is it a matter of time before such a pill is a reality? We put this question to three Leiden researchers and asked how they themselves are contributing to new cancer treatments.

Researchers at Leiden University have mapped genes that cause breast cancer cells to migrate. The Leiden toxicologists Professor Bob van de Water, Dr Wies van Roosmalen, Dr Sylvia E. Le Dévédec and colleagues studied 1500 individual genes. They found eight, including the SRPK1 gene, that regulate the…

Chemotherapy that does nothing until you irradiate it with light. Sylvestre Bonnet receives a Vici grant of 1.5 million euros for the development of this treatment. The Leiden chemist wants to build a new molecule to fight tumours that are at the time still difficult to treat.

On 11 November Professor of Gastroenterology and Hepatology, Monique van Leerdam will deliver her inaugural lecture entitled, ‘Aiming for Prevention’. Van Leerdam, who specialises in hereditary tumours, was appointed professor in July 2020. In her inaugural lecture she will discuss the importance of…

PhD defence